Thermo Fisher Scientific (TMO) Common Equity (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Common Equity for 18 consecutive years, with $51.9 billion the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at $51.9 billion, up 5.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.9 billion (up 5.22% YoY), and the FY2025 annual result was $53.4 billion, up 7.78% from the prior year.
• Common Equity was $51.9 billion for Q1 2026 at Thermo Fisher Scientific, down from $53.4 billion in the prior quarter.
• Over five years, Common Equity peaked at $53.4 billion in Q4 2025 and troughed at $41.0 billion in Q2 2022.
• Average Common Equity over 5 years is $46.9 billion, with a median of $46.7 billion recorded in 2023.
• Year-over-year, Common Equity climbed 16.97% in 2022 and climbed 3.15% in 2023.
• Over 5 years, Common Equity stood at $44.0 billion in 2022, then grew by 6.11% to $46.7 billion in 2023, then climbed by 6.05% to $49.6 billion in 2024, then grew by 7.78% to $53.4 billion in 2025, then retreated by 2.76% to $51.9 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $51.9 billion in Q1 2026, $53.4 billion in Q4 2025, and $51.0 billion in Q3 2025.